跳至主要内容
临床试验/NCT00679640
NCT00679640已完成不适用

Observational Usage and Efficacy Study of Candesartan in Heart Failure Treatment in France

AstraZeneca1 个研究点 分布在 1 个国家目标入组 450 人开始时间: 2008年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
450
试验地点
1
主要终点
Profile of patients treated with candesartan for heart failure

研究概览

简要总结

The purpose of this study is to describe the way candesartan is used in heart failure treatment in France (treatment initiation and monitoring), treatment stops occurrence and reasons for and patients clinical evolution

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • outpatients to whom candesartan has been initiated for less than 30 days or during the consultation to treat heart failure

排除标准

  • patients included in a clinical trial the last 30 days before consultation
  • patients unable to answer the questions for linguistic or cognitive reasons
  • patients who will be difficult to follow during the one year study

研究组 & 干预措施

1

Outpatients to whom candesartan has been initiated for less than 30 days or during the consultation to treat heart failure

干预措施: Candesartan (Drug)

结局指标

主要结局

Profile of patients treated with candesartan for heart failure

时间窗: At inclusion

次要结局

  • Percentage of patients taking correctly its treatment : indication, contraindication, drug titration, treatment monitoring(6 and 12 months after)
  • Percentage of patients stopping its treatment and reasons why(12 months after)
  • Percentage of hospitalisations due to heart failure and cardiovascular deaths(12 months after)

研究者

发起方
AstraZeneca
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验